In the News
Phoenix, AZ— bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139. Upon completion of the Phase I SBIR, bioSyntagma successfully demonstrated feasibility of their technology, the LightStream FloCellTM, which visually maps […]
About this project
Join us in making cancer research faster and more informative. bioSyntagma has developed a device that enables researchers and drug developers to get closer to making personalized medicine a reality by studying drug resistance in cancer patients.